Clinical trial
PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk…
NCT00326157 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00326157 |
|---|---|
| Title | PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation |
| Official title | Phase II Pilot Study on Safety of Administration of 3mg/kg/Day Three Times a Week Until Day 22 (21 Days After Transplantation Day) and 7 mg/kg Weekly From Day 29 to the End of Treatment (Day 50-8th Week) of AmBisome® in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing… |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Fungus Diseases |
| Intervention type | Drug |
| Interventions | AmBisome |
| Enrollment | 34 |
| Start date | Jun 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | May 16, 2006 |
| Last update posted | Feb 12, 2010 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: